* IRadimed Corp IRMD.OQ IRMD.O is expected to show a
rise in
quarterly revenue when it reports results on February 13 for
the period ending December 31 2024
* The Winter Springs Florida-based company is expected to
report
a 9.7% increase in revenue to $19.145 million from $17.45
million a year ago, according to the mean estimate from 2
analysts, based on LSEG data.The company's guidance on January
10 2025, for the period ended December 31, was for revenue
between $19.20 million and $19.40 million.
* LSEG's mean analyst estimate for IRadimed Corp is for
earnings
of 44 cents per share. The company's EPS guidance on October 31
2024, for the period ended December 31, was between $0.42 and
$0.45
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for IRadimed
Corp is
$65.00, above its last closing price of $60.35.
This summary was machine generated February 11 at 13:53 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)